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Synopsis 24 
Background: Urinary tract infections (UTI) are common. Antibiotic treatment is usually 25 
empirical, with the risk of under-treatment of resistant infections.   26 
Objectives: To characterise risk factors for antibiotic resistant community urine isolates using 27 
routine record linked health data.  28 
Methods: Within the National Health Service Scotland Infection Intelligence Platform, 29 
national surveillance patient-level data on community urine isolates (January 2012-June 30 
2015) were linked to hospital activity and community prescribing data. Associations between 31 
age, gender, comorbidity, care home residence, previous hospitalisations, antibiotic 32 
exposure, and resistant (any antibiotic) or MDR (DQWLELRWLFfrom categories) urinary 33 
isolates were quantified using multivariable logistic regression. 34 
Results: Of 40,984 isolates, 28% were susceptible, 45% resistant, and 27% MDR.  Exposure 35 
to  4 different antibiotics in the prior six months increased MDR risk, OR 6.81 (95%CI 5.73-36 
8.11). MDR was associated with '''cumulative exposure, in the prior six months, for 37 
any antibiotic (OR 6.54, 95%CI 5.88-7.27), nitrofurantoin (OR 8.56, 95%CI 6.56-11.18) and 38 
trimethoprim (OR 14.61, 95%CI10.53-20.27). Associations persisted for 10-12 months for 39 
nitrofurantoin (OR 2.31, 95%CI 1.93-2.76) and trimethoprim (OR 1.81, 95%CI 1.57-2.09).  40 
Increasing age, comorbidity, previous hospitalisation and care home residence were 41 
independently associated with MDR.  For resistant isolates the factors were the same but 42 
with weaker associations.  43 
Conclusion: We have demonstrated, using national capability at scale, the risk of MDR in 44 
community urine isolates for the first time and quantified the cumulative and sustained 45 
impact of antibiotic exposure.  These data will inform the development of decision support 46 
tools for UTI treatment.   47 
Introduction 48 
Antimicrobial resistance (AMR) is an increasing global health threat. 1 Resistance among 49 
invasive Gram-negative bacterial isolates in Europe and the US is high and increasing,2,3 50 
including MDR. MDR is associated with increased treatment failures and costs, and 51 
increased morbidity and mortality.4,5 52 
In Scotland, resistance among Gram-negative bacteremia remains high, particularly to 53 
antibiotics commonly prescribed for urinary tract infection (UTI).6 In 2015, Escherichia coli 54 
(E. coli) bacteremia in Scotland had an incidence of 85.5 per 100,000 population, 4.9% 55 
higher than in 2012. 6 56 
A key action of the UK Five Year Antimicrobial Resistance Strategy (AMR) (2013-2018) is 57 
better access to and use of surveillance data and improved data linkage.7 National Health 58 
Services (NHS) Scotland has developed an Infection Intelligence Platform (IIP) which has 59 
increased informatics capability and capacity to link routinely collected national data, with a 60 
particular aim of enabling patient-centred treatment through modelling patient-specific risk 61 
factors.8 62 
UTI is the second most common reason for use of antibiotics in the community.9  Initial 63 
antibiotic treatment is usually empirical, where the prescriber has no information on the 64 
causative organism or antibiotic susceptibility. In Scotland national guidance recommends 65 
nitrofurantoin or trimethoprim as first line empirical treatment of uncomplicated UTI.10 66 
However, these empirical options may not be appropriate for patients with high risk of 67 
antibiotic resistance. The aim of this study was to quantify risk factors for AMR in urine 68 
isolates using individual-level routine national data linked within the IIP.  69 
Methods 70 
NHS National Services Scotland (NSS) hosts national health and demographic data on 71 
behalf of NHS Scotland.   In Scotland all individuals have a unique patient identifier, the 72 
Community Health Index (CHI) number, which enables records for the same patient to be 73 
linked across multiple datasets.11 Within the IIP, CHI is used to link specific data then patient 74 
identifiers are removed for anonymised analysis. 75 
Data Sources 76 
The Surveillance of Antimicrobial Resistance in Urinary Isolates in Scotland (SARUIS) 77 
dataset records culture and susceptibility data for a large, representative subset of all 78 
positive urine isolates in Scotland.12  All NHS Boards are required to submit data on the first 79 
400 consecutive positive urine samples per calendar quarter. Demographic data were 80 
obtained from SARIUS. 81 
Patient level data on hospitalisations were obtained from the NSS General/Acute Inpatient 82 
and Day Case dataset (SMR01)13 and on all dispensed community NHS prescriptions in the 83 
previous 12 months were obtained from the NSS Prescribing Information System (PIS).13 84 
Cohort identification and variable classification 85 
The study cohort was identified from records with a valid CHI number in the SARUIS dataset 86 
DVSDWLHQWV\HDUVROGZLWKDclinical urine isolate taken in the community between 87 
January 2012 and June 2015. SARUIS records susceptibility data for up to 14 antibiotics for 88 
each isolate. European Committee on Antimicrobial Susceptibility Testing (EUCAST)14 89 
susceptibility testing methodology was gradually introduced in the diagnostic and reference 90 
laboratories in Scotland during 2013. This may have resulted in small proportions of isolates 91 
that would have been reported as 'susceptible' under Clinical and Laboratory Standards 92 
Institute (CSLI) 15  methodology being reported as 'resistant' under the EUCAST 93 
methodology later in the study period. Testing and reporting practice varied between 94 
laboratories meaning that not all isolates were tested against all antibiotics.  From the 95 
standard testing panel across NHS Scotland, antibiotics were grouped into seven 96 
categories12: 1. agents used for the treatment of UTI in Scotland (ciprofloxacin/ co-97 
amoxiclav/ nitrofurantoin /trimethoprim); 2. extended spectrum penicillins 98 
(ampicillin/amoxicillin); 3. first and second generation cephalosporins (cefuroxime / 99 
cefalexin); 4. third-generation cephalosporins (cefotaxime/ceftazidime); 5. carbapenems 100 
(meropenem/ertapenem); 6. aminoglycosides (gentamicin); and, 7. tetracyclines. Isolates 101 
were categorised as susceptible if susceptible to all antibiotics tested, resistant if resistant to 102 
one of the antibiotics tested; and MDR if resistant to at least one antibiotic in each of three or 103 
more categories. Patients with more than one isolate in the study period had the most 104 
resistant isolate selected, or a random isolate selected if they were in the same resistance 105 
category.   106 
Using SMR01, the number of hospital stays in the previous 12 months, and a Charlson co-107 
morbidity score16,17 derived from ICD-1018  discharge codes from the previous five years, 108 
were calculated for each patient.   109 
Using PIS, community antibiotic exposure in the previous 12 months was determined and 110 
quantified in DDDs.19 Antibiotic exposure was classified as the number of different antibiotics 111 
and, separately, as the cumulative DDD of all antibiotics, nitrofurantoin alone and 112 
trimethoprim alone, in the previous six months, and as the time interval between the urine 113 
isolate and the last prior antibiotic (in total, nitrofurantoin, trimethoprim) within 12 months.  114 
The number of different drug classes, defined as paragraphs of the legacy British National 115 
Formulary (BNF),20 a patient had dispensed in the previous 12 months was used as a co-116 
morbidity measure, in addition to the Charlson score. Care home (long term care facility in 117 
the community providing a supported care environment) residence was assigned if a patient 118 
had an admission to hospital from a care home (from SMR01) and/or was registered as a 119 
care home resident on a dispensed prescription (from PIS), in the previous 12 months. 120 
Statistical Analysis 121 
Associations between gender, age group, comorbidity, previous hospitalisation, care home 122 
residence, antibiotic exposure (measured as number of different antibiotics in previous 6 123 
months), and urine isolate susceptibility (susceptible, resistant or MDR) were quantified 124 
using multinomial logistic regression, with susceptible the reference category.  Associations 125 
significant (p<0.05) at univariate level were included in multivariate models. Where the 126 
variable was an ordered factor, the p-value for the linear trend was reported.  Measurement 127 
of the association between both temporal and cumulative antimicrobial exposure were 128 
considered in separate models for exposure to each of (i) any antibiotic (ii) nitrofurantoin and 129 
(iii) trimethoprim.  Again multinomial logistic regression was used adjusted for gender, age 130 
group, Charlson score, drug classes prescribed in the previous 12 months, number of 131 
hospital stays in previous 12 months and care home residence in the previous 12 months. 132 
A sensitivity analysis was carried out (with number of different antibiotics as the antibiotic 133 
exposure variable), excluding patients with hospitalisations in the previous 12 months to 134 
negate the potential effect of any hospital prescribing on the associations observed as 135 
patient-level hospital prescribing data was not available.   A separate sub-group analysis 136 
was conducted including isolates that had not been tested against at least one antibiotic 137 
from all seven categories.   138 
Data manipulation was carried out in SPSS version 21 and analyses in R version 3.2.0. 139 
Ethical approval 140 
All study data were generated during routine care and had all patient identifiers removed 141 
prior to analysis. NSS Privacy Advisory Committee approval was granted and all analysis 142 
adhered to NSS Information Governance Policy and Procedures.  143 
Results  144 
Within the study period 40,984 (62%) of 66,194 urine isolates in SARUIS met the inclusion 145 
criteria. Of these, 11,674 (28%) were susceptible, 18,445 (45%) were resistant, and 10,892 146 
(27%) MDR, and E. coli accounted for 73% of all isolates (Table 1). More than half of all 147 
LVRODWHVZHUHIURPSHRSOH\HDUVROG79% were from female patients and 9% were from 148 
care home residents (Table 1). One third of patients had D&KDUOVRQVFRUHRI but almost 149 
three-quarters had been prescribed drugs from t5 classes in the previous 12 months, and 150 
36% had a hospital stay in the previous 12 months (Table 1). Just over a third of patients 151 
had no antibiotic prescriptions in the prior six months and 5% had at least four different 152 
antibiotics (Table 1).  A total of 30% had 14 DDD of antibiotic in the preceding six months 153 
and the mean time since last antibiotic prescription in the prior 12 months was 75 days 154 
(SD=90)  the median was 35 days (IQR=104).  155 
In univariate analyses, male gender, increasing age, comorbidity, hospitalisation, care home 156 
residence, number of different drug classes and different antibiotics in the previous six 157 
months were all associated with increased risk of having resistant and MDR isolates (Table 158 
2). Associations remained in adjusted analysis, with higher MDR risk associated with being 159 
male (OR 1.17, 95%CI 1.09-1.26), older (OR for  versus <25 years old: 1.81, 95%CI 160 
1.56-2.10), higher Charlson scores &KDUOVRQ5 versus 0 OR 1.31 (95%CI 1.11-1.56)), 161 
numbers of previously prescribed drug classes 25IRUversus 0-4: 2.06, 95%CI 1.73-162 
2.45), numbers of previous admissions 25IRUversus 0: 1.82, 95%CI 1.56-2.13), and 163 
care home residence  (OR 3.36, 95%CI 2.95-3.83) (Table 2).  Having prescriptions for 164 
different antibiotics in the previous six months had the highest association with MDR, of any 165 
variable category, in adjusted analysis (OR 6.81, 95%CI 5.73-8.11) (Table 2). Resistance to 166 
one antibiotic had similar associations as MDR but with weaker associations for most 167 
covariates, with care home residence (OR 2.16, 95%CI 1.90-2.45) and an increasing 168 
number of different antibiotics prescribed in the previous six months (versus 0 OR 2.79, 169 
95%CI 2.36-3.31) having the strongest associations with resistance.   170 
The sensitivity analysis excluding patients with hospitalisations in the previous 12 months 171 
comprised 26,020 patients (64% of whole cohort). Age was no longer significantly 172 
associated with resistant isolates (p=0.961) but remained strongly associated with MDR 173 
(p<0.001), and the association between male gender and MDR was not significant (p=0.08). 174 
Other associations, particularly higher numbers of different antibiotics, were similar to the 175 
main cohort analysis (Table S1). The sub-group analysis including only isolates not tested 176 
against at least one drug from all seven categories of antibiotics comprised of 6,386 patients 177 
(15.5% of cohort). Most associations with resistance and MDR were similar to the main 178 
analysis with the exception of gender not being significant and previous hospitalisation not 179 
being associated with resistant isolates (Table S2). 180 
Cumulative exposure in the prior six months had dose-response effects on resistance and 181 
MDR, for total antibiotic, nitrofurantoin, and trimethoprim exposures (Figures 1 & 2).  For 182 
MDR, ''' versus no antibiotics in the previous six months, had an OR 6.54 (95%CI 183 
5.88-7.27) for total antibiotic exposure, 8.56 (95%CI 6.56-11.18) for nitrofurantoin, and 14.61 184 
(95%CI 10.53-20.27) for trimethoprim (Figure 2).     185 
There were temporal associations between antibiotic exposure and resistance, particularly 186 
MDR (Table 3). Exposure to any antibiotic in the previous one month had an adjusted odds 187 
of MDR of 2.89 (95%CI 2.67-3.13) compared to no antibiotics, reducing to an odds of 1.16 188 
(95%CI 1.00-1.34) if the last exposure was 10-12 months previously (Table 3). Exposure to 189 
trimethoprim and to nitrofurantoin, compared to no antibiotics, in the previous one month had 190 
similar associations with MDR as for any antibiotic exposure, but effects persisted for longer 191 
and were still highly significant for exposure 10-12 months previously (nitrofurantoin OR 192 
2.31, 95%CI 1.93-2.76), and trimethoprim OR 1.81 (95%CI 1.57-2.09) (Table 3).    193 
Discussion 194 
This study is, as far as we know, the first to use national patient-level data linkage to 195 
characterise risk factors for AMR in community urine isolates and to examine MDR. We 196 
found that antibiotic exposure in the previous six months was strongly associated with MDR, 197 
and the effect was stronger with greater cumulative exposure to any antibiotics, to 198 
nitrofurantoin and to trimethoprim. The risk of MDR remained elevated following last 199 
exposure to any antibiotics for 7-9 months and to nitrofurantoin and trimethoprim for 10-12 200 
months. We also found increasing age, comorbidity (Charlson score and drug classes), 201 
hospitalisation in the previous 12 months and care home residence were significantly 202 
associated with resistance and MDR after adjustment of other factors. 203 
Previous studies of resistance risk factors in community urine isolates have focussed on 204 
H[SRVXUHWRDVLQJOHRUµDQ\¶undefined antibiotic and associations of resistance to one or 205 
two antibiotics, without examining MDR. Such studies were small scale (n=398-8833), in 206 
single regions rather than at national level and were over 10 years old.21-23 Our study 207 
established that exposure to even one type of antibiotic within the previous six months was 208 
associated with resistance (OR=1.19 95%CI, 1.12-1.26) after adjustment for other factors. 209 
Steinke et al reported isolates with trimethoprim resistance were strongly independently 210 
associated with trimethoprim exposure (OR 4.35, 95%CI 3.03-5.73) and to any other 211 
antibiotics (OR 1.32, 95%CI1.10-1.60) in the six month prior to the isolate.21 Donnan et al  212 
UHSRUWHGWULPHWKRSULPUHVLVWDQFHZDVLQGHSHQGHQWO\DVVRFLDWHGZLWKSUHVFULSWLRQIRU213 
trimethoprim (OR 1.22, 95%CI 1.16-DQGWRSUHVFULSWLRQIRURWKHUDQWLELRWLFV25 214 
1.18, 95%CI 1.06-1.32) in the six months prior to the isolate.22 Dromigny et al  reported prior 215 
exposure to any antibiotics was an independent risk factor for trimethoprim/sulfamethoxazole 216 
resistance (OR 2.4 (95%CI1.4-4.1)).23 Our study demonstrated a relationship between prior 217 
antibiotic use and resistance to single antibiotics but, more importantly, to MDR. We have 218 
established that use of one antibiotic within six months of the isolate to be independently 219 
associated with MDR (OR 1.57; 95%CI, 1.46-1.68). 220 
Evidence for a relationship between cumulative antibiotic exposure and resistance is sparse. 221 
Hillier et al in a study in 10 UK general practices (GP) reported trimethoprim resistance was 222 
significantly associated with the number of trimethoprim courses in the previous 12 months 223 
with OR 2.08 (95%CI 1.34-3.22) for one prescription rising to OR 7.53 (95%CI 2.71-20.88) 224 
for prescriptions.24 Hay et al in a study in 12 UK GP practices reported OR 3.14 (95%CI 225 
0.63-15.6) for resistance to amoxicillin and/or trimethoprim DVVRFLDWHGZLWKFRXUVHVRI226 
antibiotics in 12 months in patients with E. coli urine isolates.25  Our study established 227 
increasing cumulative exposure to antibiotics was associated with resistance. Moreover it 228 
demonstrates a dose response relationship between cumulative total antibiotic, nitrofurantoin 229 
or trimethoprim exposure and MDR which has not been reported previously.   230 
The period of increased risk of resistance following antibiotic exposure is important. A meta-231 
analysis (14,348 participants) by Costelloe et al demonstrated a pooled OR of 1.33 (95%CI 232 
1.15-1.53) for associations with resistance in those exposed to trimethoprim, amoxicillin or 233 
any antibiotic in the previous 12 months, but only included resistance to single antibiotics.26  234 
In a more recent study, Duffy et al found that associations with trimethoprim use and 235 
resistance were not significant beyond 84 days since last exposure in community urinary 236 
isolates from children (n=1373).27 Importantly our study extends this evidence to the impact 237 
of antibiotic use on MDR. We found the effect on MDR of any antibiotic exposure was still 238 
evident at seven-nine months (OR 1.27, 95%CI 1.12-1.45). For individuals whose most 239 
recent exposure to trimethoprim was up to 10-12 months prior to the positive isolate we 240 
found the effect on MDR was still significant at 10-12 months post-exposure (OR 1.80, 241 
95%CI 1.66-1.95) and the effect was even greater following exposure to nitrofurantoin (OR 242 
2.31, 95%CI 1.93-2.76).  243 
Previous reports of an association between nitrofurantoin resistance in E coli isolates in 244 
Finland were at population level rather than individual level.28 Our study is, as far as we 245 
know, the first to establish patient-level associations between nitrofurantoin exposure and 246 
resistance and MDR. +HUHZHUHSRUWWKDWH[SRVXUHWR'''s of nitrofurantoin in the 247 
previous six months increased OR of MDR to 8.56 (95%CI 6.56-11.18).  248 
We identified risk factors other than antibiotic exposure to be associated with increased odds 249 
of MDR. The adjusted effect of care home residence we report (OR 3.36, 95%CI 2.95-3.83) 250 
was similar to that adjusted OR reported by Faine et al (4.17, 95% CI 1.13-15.3) for MDR in 251 
360 patients with UTI in an emergency department setting.29 We found that as number of 252 
hospitalisations in the previous 12 months increases so too did the odds of MDR. Our finding 253 
is different to a small study (n=828) by Steinke et al, in a single region in Scotland, which 254 
found that hospitalisation in the previous six months was not independently associated with 255 
trimethoprim resistance.30 Male gender and increasing age have been associated with 256 
resistance in other studies and our findings are similar.21,22,29,31 257 
Of the risk factors assessed in this study, antibiotic exposure is the most important as it had 258 
the strongest association with resistance and is modifiable through antibiotic stewardship 259 
interventions. There is evidence that in some uncomplicated UTIs in adult females, 260 
symptomatic relief with ibuprofen is non inferior to antibiotics.32 Our results should support 261 
efforts to reduce unnecessary use of any antibiotics to reduce selection pressure for 262 
resistance and especially MDR. The recommendation of the European Association of 263 
Urology 33 to review and consider discontinuation of antibiotic prophylaxis of UTI is important 264 
given the association between cumulative use of antibiotics and MDR demonstrated in our 265 
study. 266 
A recent review highlighted the importance of linkage of prescription and outcome data to 267 
improve understanding of the risks of and outcomes from AMR in UTI and called for the 268 
outputs from such data linkage studies to inform clinical decision making, prescribing 269 
practice and guideline development34. Our findings demonstrate that the risk of resistance to 270 
antibiotics, especially those commonly used for treatment of UTI is influenced by factors 271 
such as age, gender, comorbidity, previous hospitalisation, care home residence and 272 
antibiotic exposure.   273 
Strengths of our study include that it was conducted at national level using data collected as 274 
part of routine clinical practice. As the data source for urine isolates was a national database 275 
these data should be representative of all urine isolates collected in the community. The 276 
inclusion of MDR as an outcome was a further strength as previous studies have focused on 277 
resistance to single antibiotics or a small subgroup of antibiotics, which takes no account of 278 
MDR.21-23  We also examined cumulative and temporal associations between resistance and 279 
exposure to all antibiotics, nitrofurantoin and trimethoprim. The sensitivity analysis excluding 280 
patients with hospitalisations in the previous 12 months, removes any impact on resistance 281 
of antibiotic exposure in hospital, which presently is not captured at individual patient level 282 
across all of Scotland, or of recent transmission in hospital.  283 
The work has several limitations that may limit our findings generalizability to all UTIs. 284 
Samples collected in the community and submitted for culture and susceptibility to 285 
microbiology departments will be biased towards resistance as samples may only be 286 
submitted in complicated cases or in cases where patients have failed on initial empirical 287 
treatment. This bias while overestimating the true prevalence of resistance in urine isolates 288 
should not impact on the association between resistance and other variables.  Furthermore, 289 
the susceptibility data included in the analysis is dependent on testing carried out in, and 290 
national reporting from, individual diagnostic laboratories so we did not have results for all 291 
isolates tested against all antibiotics. However, sub-group analysis on those isolates (n = 292 
6386; 16% of total isolates) not tested against all seven categories of antibiotics yielded 293 
similar results.  294 
This national level data linkage study has for the first time as far as we know quantified the 295 
risk of MDR associated in community urine isolates. We demonstrated a dose-response 296 
relationship with MDR increasing with increased cumulative antibiotics exposure. The risk of 297 
MDR was highest within one month of antibiotic exposure but an effect for nitrofurantoin and 298 
trimethoprim remained for up to 12 months after the last exposure. These data will be used 299 
to design and test a clinical decision support tool which could enable clinicians to identify 300 
patients, at the point of writing the prescription, who are at high risk of resistance. 301 
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Table 1: Patient and isolate characteristics by resistance classificationa  
 
Susceptible Resistant MDR Total 
n (%) n (%) n (%) n (total %) 
Organism Group     
Escherichia coli 10385 (34.6) 10966 (36.5) 8687 (28.9) 30038 (73.3) 
Klebsiella spp. 2 (0.1) 2271 (74.5) 775 (25.4) 3048 (7.4) 
Enterococci 220 (9.2) 1978 (82.7) 193 (8.1) 2391 (5.8) 
Proteus spp. 70 (4.5) 1044 (66.8) 448 (28.7) 1562 (3.8) 
Other 970 (24.6) 2186 (55.4) 789 (20.0) 3945 (9.6) 
Gender     
Female 9704 (29.9) 14258 (43.9) 8518 (26.2) 32480 (79.3) 
Male 1943 (22.8) 4187 (49.2) 2374 (27.9) 8504 (20.7) 
Age group     
16-24 1112 (39.7) 1249 (44.6) 441 (15.7) 2802 (6.8) 
25-34 1047 (36.4) 1342 (46.7) 487 (16.9) 2876 (7.0) 
35-44 1016 (35.2) 1260 (43.6) 611 (21.2) 2887 (7.0) 
45-54 1334 (32.4) 1794 (43.6) 990 (24.0) 4118 (10) 
55-64 1648 (30.7) 2302 (42.9) 1414 (26.4) 5364 (13.1) 
65-74 2272 (27.8) 3672 (45.0) 2214 (27.1) 8158 (19.9) 
75-84 2174 (23.9) 4244 (46.6) 2694 (29.6) 9112 (22.2) 
t85 1044 (18.4) 2582 (45.6) 2041 (36.0) 5667 (13.8) 
Charlson score     
0 4110 (29.7) 6143 (44.4) 3580 (25.9) 13833 (33.8) 
1-2 1880 (21.1) 4107 (46.1) 2914 (32.7) 8901 (21.7) 
3-4 497 (16.0) 1453 (46.9) 1149 (37.1) 3099 (7.6) 
t5 256 (15.1) 792 (46.8) 645 (38.1) 1693 (4.1) 
Unknownb 4904 (36.4) 5950 (44.2) 2604 (19.3) 13458 (32.8) 
Drug classes in previous 12 monthsc    
0-4 4285 (40.2) 4578 (42.9) 1801 (16.9) 10664 (26.0) 
5-9 3976 (30.8) 5990 (46.4) 2951 (22.8) 12917 (31.5) 
10-14 2298 (22.6) 4650 (45.8) 3204 (31.6) 10152 (24.8) 
15-19 838 (16.4) 2296 (45.0) 1970 (38.6) 5104 (12.5) 
t20 250 (11.6) 931 (43.4) 966 (45.0) 2147 (5.2) 
Hospital stays in previous 12 months   
0 8522 (32.8) 11627 (44.7) 5871 (22.6) 26020 (63.5) 
1 1892 (24.2) 3609 (46.1) 2324 (29.7) 7825 (19.1) 
2 673 (19.3) 1621 (46.6) 1185 (34.1) 3479 (8.5) 
3 266 (16.1) 718 (43.5) 668 (40.4) 1652 (4.0) 
t4 294 (14.6) 870 (43.3) 844 (42.0) 2008 (4.9) 
Care home residence     
Yes 350 (10.0) 1559 (44.4) 1603 (45.6) 3512 (8.6) 
No 11297 (30.1) 16886 (45.1) 9289 (24.8) 37472 (91.4) 
Number of different antibiotics in previous 6 months   
0 5456 (38.0) 6415 (44.7) 2493 (17.4) 14364 (35.0) 
1 3865 (30.0) 5818 (45.2) 3197 (24.8) 12880 (31.4) 
2 1652 (20.6) 3714 (46.3) 2656 (33.1) 8022 (19.6) 
3 490 (13.1) 1683 (45.0) 1563 (41.8) 3736 (9.1) 
t4 184 (9.3) 815 (41.1) 983 (49.6) 1982 (4.8) 
Total cases 11647 (28.4) 18445 (45.0) 10892 (26.6) 40984 
a Isolates were categorised as susceptible if susceptible to all antibiotics tested, resistant if resistant to one of the antibiotics tested; and MDR if 
resistant to at least one antibiotic in each of three or more categories.  b An unknown Charlson score suggests the patient had no hospital admissions 
in the previous 5 years, therefore a Charlson score could not be calculated.  c Drug classes defined as the number of different British National 
Formulary paragraphs, for example, ACE-inhibitors (BNF paragraph 2.5.5.1) would be considered a different drug class to angiotensin receptor 
blockers (BNF paragraph 2.5.5.2). 
Table 2: Multivariable analysis of risk factors ʹ resistant cases and MDR compared to susceptible cases  
 
Resistant isolate compared to  
susceptible isolatea 
 MDR isolate compared to  
susceptible isolatea 
Unadjusted Adjusted Unadjusted Adjusted 
OR (95% CI) OR (95% CI) p-valueb OR (95% CI) OR (95% CI) p-valueb 
Gender       
Female 1 1 <0.001 1 1 <0.001 
Male 1.47 (1.38-1.56) 1.36 (1.27-1.44)  1.39 (1.3-1.49) 1.17 (1.09-1.26)  
Age group       
16-24 1 1 0.031 1 1 <0.001 
25-34 1.14 (1.02-1.28) 1.11 (0.99-1.25)  1.17 (1.01-1.37) 1.11 (0.95-1.30)  
35-44 1.10 (0.98-1.24) 1.00 (0.89-1.12)  1.52 (1.31-1.76) 1.29 (1.10-1.50)  
45-54 1.20 (1.08-1.33) 1.00 (0.90-1.12)  1.87 (1.63-2.15) 1.40 (1.21-1.61)  
55-64 1.24 (1.12-1.38) 0.96 (0.86-1.06)  2.16 (1.90-2.47) 1.41 (1.23-1.62)  
65-74 1.44 (1.31-1.58) 1.00 (0.91-1.11)  2.46 (2.17-2.78) 1.37 (1.20-1.57)  
75-84 1.74 (1.58-1.91) 1.09 (0.98-1.21)  3.12 (2.76-3.54) 1.47 (1.28-1.68)  
t85 2.20 (1.98-2.45) 1.21 (1.07-1.37)  4.93 (4.31-5.63) 1.81 (1.56-2.10)  
Charlson score       
0 1 1  1 1  
1-2 1.46 (1.37-1.56) 1.13 (1.05-1.22) 0.001 1.78 (1.65-1.91) 1.11 (1.02-1.21) 0.011 
3-4 1.96 (1.75-2.18) 1.30 (1.15-1.46) <0.001 2.65 (2.37-2.98) 1.27 (1.12-1.44) <0.001 
t5 2.07 (1.79-2.40) 1.36 (1.16-1.59) <0.001 2.89 (2.49-3.37) 1.31 (1.11-1.56) 0.002 
Unknownc 0.81 (0.77-0.86) 0.98 (0.92-1.04) 0.471 0.61 (0.57-0.65) 0.89 (0.82-0.95) 0.002 
Drug classes prescribed in previous 12 monthsd      
0-4 1 1 <0.001 1 1 <0.001 
5-9 1.41 (1.33-1.49) 1.13 (1.06-1.20)  1.77 (1.64-1.90) 1.07 (0.99-1.16)  
10-14 1.89 (1.77-2.02) 1.22 (1.13-1.32)  3.32 (3.07-3.58) 1.35 (1.23-1.48)  
15-19 2.56 (2.35-2.80) 1.42 (1.27-1.57)  5.59 (5.07-6.17) 1.71 (1.51-1.92)  
t20 3.49 (3.01-4.03) 1.61 (1.37-1.90)  9.19 (7.92-10.68) 2.06 (1.73-2.45)  
Number of hospital stays in previous 12 months      
0 1 1 0.002 1 1 <0.001 
1 1.40 (1.31-1.49) 1.09 (1.01-1.17)  1.78 (1.66-1.91) 1.16 (1.07-1.26)  
2 1.77 (1.61-1.94) 1.19 (1.07-1.31)  2.56 (2.31-2.83) 1.36 (1.21-1.52)  
3 1.98 (1.71-2.28) 1.21 (1.04-1.41)  3.65 (3.15-4.22) 1.70 (1.45-2.00)  
t4 2.17 (1.89-2.48) 1.25 (1.08-1.45)  4.17 (3.63-4.78) 1.82 (1.56-2.13)  
Care home residence       
No 1 1 <0.001 1 1 <0.001 
Yes 2.98 (2.65-3.35) 2.16 (1.90-2.45)  5.57 (4.95-6.27) 3.36 (2.95-3.83)  
Number of different antibiotics prescribed in previous 6 months     
0 1 1 <0.001 1 1 <0.001 
1 1.28 (1.21-1.35) 1.19 (1.12-1.26)  1.81 (1.69-1.94) 1.57 (1.46-1.68)  
2 1.91 (1.79-2.05) 1.64 (1.53-1.77)  3.52 (3.26-3.80) 2.65 (2.44-2.88)  
3 2.92 (2.63-3.25) 2.34 (2.09-2.62)  6.98 (6.24-7.81) 4.63 (4.11-5.22)  
t4 3.77 (3.20-4.44) 2.79 (2.36-3.31)  11.69 (9.92-13.78) 6.81 (5.73-8.11)  
a Isolates were categorised as susceptible if susceptible to all antibiotics tested, resistant if resistant to one of the antibiotics tested; and MDR if resistant to at 
least one antibiotic in each of three or more categories.  b Linear trend test, evaluated by including variable as an ordered factor in the multinomial logistic 
regression model (excluding gender, care home and Charlson score as not ordered factors).  c An unknown Charlson score suggests the patient had no hospital 
admissions in the previous 5 years, therefore a Charlson score could not be calculated.  d Drug classes defined as the number of different British National 
Formulary paragraphs, for example, ACE-inhibitors (BNF paragraph 2.5.5.1) would be considered a different drug class to angiotensin receptor blockers (BNF paragraph 
2.5.5.2).   
Table 3: Temporal antibiotic exposure ʹ time since last antibiotic in previous 12 months 
 
Resistant isolate compared to  
susceptible isolatea 
 MDR isolate compared to  
susceptible isolatea 
Unadjusted Adjusted Unadjusted Adjusted 
OR (95% CI) OR (95% CI) p-value b  OR (95% CI) OR (95% CI) p-value b 
All antibiotics       
No antibiotics 1 1 0.001 1 1 <0.001 
<=1 month 1.96 (1.85-2.09) 1.62 (1.52-1.73)  4.21 (3.91-4.53) 2.89 (2.67-3.13)  
2-3 months 1.75 (1.63-1.89) 1.38 (1.28-1.49)  3.31 (3.04-3.61) 2.08 (1.90-2.28)  
4-6 months 1.35 (1.24-1.46) 1.12 (1.03-1.22)  2.01 (1.82-2.22) 1.39 (1.25-1.54)  
7-9 months 1.29 (1.17-1.42) 1.11 (1.00-1.23)  1.72 (1.52-1.94) 1.27 (1.12-1.45)  
10-12 months 1.18 (1.06-1.32) 1.06 (0.94-1.19)  1.44 (1.25-1.66) 1.16 (1.00-1.34)  
Nitrofurantoin       
No antibiotics 1 1  1 1  
<= 1 month 1.94 (1.77-2.12) 1.58 (1.43-1.74) <0.001 4.61 (4.16-5.11) 3.06 (2.74-3.41) <0.001 
2-3 months 2.07 (1.86-2.31) 1.60 (1.43-1.80) <0.001 5.42 (4.82-6.08) 3.28 (2.90-3.71) <0.001 
4-6 months 2.21 (1.96-2.50) 1.71 (1.50-1.94) <0.001 5.23 (4.59-5.97) 3.13 (2.73-3.60) <0.001 
7-9 months 1.94 (1.68-2.24) 1.52 (1.31-1.76) <0.001 4.19 (3.59-4.89) 2.55 (2.17-3.00) <0.001 
10-12 months 1.90 (1.62-2.22) 1.51 (1.29-1.78) <0.001 3.64 (3.07-4.33) 2.31 (1.93-2.76) <0.001 
Other antibiotic in previous 
12 months 
1.51 (1.43-1.59) 1.28 (1.21-1.36) <0.001 2.36 (2.20-2.53) 1.74 (1.61-1.88) <0.001 
Trimethoprim       
No antibiotics 1 1  1 1  
<= 1 month 1.79 (1.66-1.93) 1.55 (1.43-1.68) <0.001 3.69 (3.38-4.02) 2.72 (2.48-2.98) <0.001 
2-3 months 1.91 (1.75-2.09) 1.49 (1.35-1.63) <0.001 4.01 (3.62-4.44) 2.44 (2.19-2.72) <0.001 
4-6 months 1.70 (1.54-1.87) 1.32 (1.20-1.46) <0.001 3.32 (2.98-3.70) 2.00 (1.78-2.24) <0.001 
7-9 months 1.65 (1.47-1.84) 1.29 (1.15-1.45) <0.001 2.95 (2.60-3.35) 1.80 (1.57-2.06) <0.001 
10-12 months 1.53 (1.35-1.73) 1.21 (1.07-1.37) 0.003 2.89 (2.52-3.31) 1.81 (1.57-2.09) <0.001 
Other antibiotic in previous 
12 months 
1.55 (1.46-1.64) 1.29 (1.21-1.37) <0.001 2.58 (2.39-2.78) 1.80 (1.66-1.95) <0.001 
Data adjusted for: gender, age group, Charlson score, drug classes in previous 12 months, hospital stays in previous 12 
months and care home residence in previous 12 months. 
a Isolates were categorised as susceptible if susceptible to all antibiotics tested, resistant if resistant to one of the antibiotics tested; and MDR if 
resistant to at least one antibiotic in each of three or more categories.  b Linear trend test, evaluated by including variable as an ordered factor in 
the multinomial logistic regression model (all antibiotics only). 
 
Figure 1: Effect of cumulative antibiotic exposure in the 6 months prior to infection ʹ resistant isolates [OR (95% CI)] 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of cumulative antibiotic exposure in the 6 months prior to infection ʹ MDR isolates [OR (95% CI)] 
 
 
 
 
 
 
 
 
 
Figures 1 and 2: Data adjusted for: gender, age group, Charlson score, drug classes in previous 12 months, hospital stays in previous 12 months and care home residence. 
 
